3-氨基-5-甲基噻吩-2-甲腈 | 83060-73-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 中文名称: 3-氨基-5-甲基噻吩-2-甲腈
• 中文别名: 3-氨基-5-甲基噻吩-2-氰基
• 英文名称: 3-amino-5-methylthiophene-2-carbonitrile
• CAS: 83060-73-5
• 化学式: C₆H₆N₂S
• mdl: MFCD08689594
• 分子量: 138.193
• InChiKey: QRYUNVRWSZIEDZ-UHFFFAOYSA-N

物化性质

• 沸点：
  355.4±42.0 °C(Predicted)
• 密度：
  1.26±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.166
• 拓扑面积：
  78
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2934999090

反应信息

• 作为反应物：
  描述：

  3-氨基-5-甲基噻吩-2-甲腈 在 sodium hydroxide 、 硫化氢 作用下， 以 吡啶 、 三乙胺 为溶剂， 反应 19.58h， 生成 2,6-dimethyl-4-(methylthio)thieno<3,2-d>pyrimidine
  参考文献：
  名称：

  从α-炔腈方便地合成取代的3-氨基噻吩-2-腈并将其转化为噻吩并[3,2- d ]嘧啶

  摘要：

  从迄今未知的3-氨基-5-甲基-（或5-苯基）噻吩-2-腈7和8合成了几种新颖的2,4,6-三取代噻吩并[3,2- d ]嘧啶。通过将巯基乙腈（原位生成）共轭添加到取代的乙炔腈4和5中，并使中间体乙烯基硫醚脱环，可以一步制得邻氨基甲酸酯7和8。

  DOI：

  10.1002/jhet.5570230631
• 作为产物：
  描述：

  3-amino-5-methylthiophene-2-thiocarboxamide 在 三丁基氧化锡 作用下， 以 苯 为溶剂， 反应 0.5h， 以93%的产率得到3-氨基-5-甲基噻吩-2-甲腈
  参考文献：
  名称：

  Facile conversion of primary thioamides into nitriles with butyltin oxides

  摘要：

  DOI：

  10.1021/jo00144a043

文献信息

• [EN] HPK1 INHIBITORS AND METHODS OF USING SAME<br/>[FR] INHIBITEURS DE HPK1 ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV HEALTH NETWORK

  公开号：WO2016205942A1

  公开（公告）日：2016-12-29

  Thienopyridinone compounds of Formula (I) and pharmaceutically acceptable salts thereof are described. In these compounds, one of X1; X2, and X3 is S and the other two are each independently CR, wherein R and all other variables are as defined herein. The compounds are shown to inhibit HPK1 kinase activity and to have in vivo antitumor activity. The compounds can be effectively combined with pharmaceutically acceptable carriers and also with other immunomodulatory approaches, such as checkpoint inhibition or inhibitors of tryptophan oxidation. Formula (I).

  Thienopyridinone化合物的化学式（I）及其药用盐已被描述。在这些化合物中，X1、X2和X3中的一个是S，另外两个分别是独立的CR，其中R和所有其他变量如本文所定义。已证明这些化合物能抑制HPK1激酶活性并具有体内抗肿瘤活性。这些化合物可以有效地与药用载体以及其他免疫调节方法结合使用，例如检查点抑制或色氨酸氧化抑制剂。化学式（I）。
• MODULATION OF CHEMOSENSORY RECEPTORS AND LIGANDS ASSOCIATED THEREWITH
  申请人：Tachdjian Catherine

  公开号：US20110224155A1

  公开（公告）日：2011-09-15

  The present invention includes methods for identifying modifiers of chemosensory receptors and their ligands, e.g., by determining whether a test entity is suitable to interact with one or more interacting sites within the Venus flytrap domains of the chemosensory receptors, and modifiers capable of modulating chemosensory receptors and their ligands. The present invention also includes modifiers of chemosensory receptors and their ligands having Formula (I), its subgenus, and specific compounds. Furthermore, the present invention includes ingestible compositions comprising the modifiers of chemosensory receptors and their ligands and methods of using the modifiers of chemosensory receptors and their ligands to enhance the sweet taste of an ingestible composition or treat a condition associated with a chemosensory receptor. In addition, the present invention include processes for preparing the modifiers of chemosensory receptors and their ligands.

  本发明包括识别化学感受受体及其配体的修饰剂的方法，例如通过确定测试实体是否适合与化学感受受体的捕蝇草结构域中的一个或多个相互作用位点发生相互作用，并且能够调节化学感受受体及其配体的修饰剂。本发明还包括化学感受受体及其配体的修饰剂，其具有式（I）、其亚属和具体化合物。此外，本发明还包括包含化学感受受体及其配体的修饰剂的可食用组合物以及使用化学感受受体及其配体的修饰剂增强可食用组合物的甜味或治疗与化学感受受体相关的疾病的方法。此外，本发明还包括制备化学感受受体及其配体的修饰剂的过程。
• Modulation of chemosensory receptors and ligands associated therewith
  申请人：Tachdjian Catherine

  公开号：US08633186B2

  公开（公告）日：2014-01-21

  The present invention includes methods for identifying modifiers of chemosensory receptors and their ligands, e.g., by determining whether a test entity is suitable to interact with one or more interacting sites within the Venus flytrap domains of the chemosensory receptors, and modifiers capable of modulating chemosensory receptors and their ligands. The present invention also includes modifiers of chemosensory receptors and their ligands having Formula (I), its subgenus, and specific compounds. Furthermore, the present invention includes ingestible compositions comprising the modifiers of chemosensory receptors and their ligands and methods of using the modifiers of chemosensory receptors and their ligands to enhance the sweet taste of an ingestible composition or treat a condition associated with a chemosensory receptor. In addition, the present invention include processes for preparing the modifiers of chemosensory receptors and their ligands.

  本发明涉及识别化学感受器及其配体的修饰剂的方法，例如，通过确定测试实体是否适合与化学感受器的食虫植物结构域内的一个或多个相互作用位点相互作用来确定。本发明还包括能够调节化学感受器及其配体的修饰剂。本发明还包括具有公式（I）、其亚属和特定化合物的化学感受器及其配体的修饰剂。此外，本发明包括包含化学感受器及其配体的修饰剂的可食用组合物，并使用化学感受器及其配体的修饰剂来增强可食用组合物的甜味或治疗与化学感受器相关的疾病的方法。此外，本发明还包括制备化学感受器及其配体的修饰剂的方法。
• Modulation of chemosensory receptors and ligands associated
  申请人：Senomyx, Inc.

  公开号：EP2568287A2

  公开（公告）日：2013-03-13

  The present invention includes methods for identifying modifiers of chemosensory receptors and their ligands, e.g., by determining whether a test entity is suitable to interact with one or more interacting sites within the Venus flytrap domains of the chemosensory receptors, and modifiers capable of modulating chemosensory receptors and their ligands. The present invention also includes modifiers of chemosensory receptors and their ligands having Formula (I), its subgenus, and specific compounds. Furthermore, the present invention includes ingestible compositions comprising the modifiers of chemosensory receptors and their ligands and methods of using the modifiers of chemosensory receptors and their ligands to enhance the sweet taste of an ingestible composition or treat a condition associated with a chemosensory receptor. In addition, the present invention includes processes for preparing the modifiers of chemosensory receptors and their ligands.

  本发明包括鉴定化感受体及其配体的修饰剂的方法，例如，通过确定试验实体是否适合与化感受体金星捕蝇草结构域内的一个或多个相互作用位点相互作用，以及能够修饰化感受体及其配体的修饰剂。本发明还包括具有式（I）、其亚属和特定化合物的化感受体及其配体的调节剂。此外，本发明还包括包含化感受体修饰剂及其配体的可食用组合物，以及使用化感受体修饰剂及其配体提高可食用组合物甜味或治疗与化感受体相关疾病的方法。此外，本发明还包括制备化感受体修饰剂及其配体的工艺。
• HPK1 inhibitors and methods of using same
  申请人：University Health Network

  公开号：US11059832B2

  公开（公告）日：2021-07-13

  Thienopyridinone compounds of Formula (I) and pharmaceutically acceptable salts thereof are described. In these compounds, one of X1; X2, and X3 is S and the other two are each independently CR, wherein R and all other variables are as defined herein. The compounds are shown to inhibit HPK1 kinase activity and to have in vivo antitumor activity. The compounds can be effectively combined with pharmaceutically acceptable carriers and also with other immunomodulatory approaches, such as checkpoint inhibition or inhibitors of tryptophan oxidation. Formula (I).

  描述了式 (I) 的噻吩并吡啶酮化合物及其药学上可接受的盐类。在这些化合物中，X1、X2 和 X3 中的一个为 S，另外两个各自独立地为 CR，其中 R 和所有其他变量如本文所定义。研究表明，这些化合物可抑制 HPK1 激酶活性，并具有体内抗肿瘤活性。这些化合物可与药学上可接受的载体有效结合，也可与其他免疫调节方法结合，如检查点抑制或色氨酸氧化抑制剂。式 (I).